Comparative efficacy of two broad-spectrum antiviral drugs universally used for the treatment of COVID-19 in children

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background: Data on the efficacy and safety of antiviral drugs in children with COVID-19 are limited and do not allow a definitive conclusion about the advantages of any drug.

Objective: Comparative evaluation of the efficacy of two antiviral drugs with different mechanisms of action in the treatment of COVID-19 in children: oral umifenovir (UMF) and (interferon) IFN for intranasal use.

Materials and methods: A retrospective analysis of 130 medical records of children aged 2 to 18 years with RT-PCR-confirmed COVID-19 who received inpatient treatment during 2020–2022, during the period of spread of the initial SARS-CoV-2 variants and early Omicron variants, was conducted. The study included children with non-severe COVID-19 (moderate form 65.4%, pneumonia 36%) without risk factors who received umifenovir (UMF, n=86) or intranasal recombinant alpha-2b interferon (IFN, n=44), discharged from the hospital with recovery and a control RT-PCR test for SARS-CoV-2.

Results: In mild COVID-19, the duration of weakness was shorter in those receiving UMF than in the IFN group (1.83±0.79 vs. 2.73±1.35 days, p=0.030; difference 0.9 days [95% CI: 0.2–1.6]), and in moderate COVID-19, the duration of rhinitis was shorter (4.8±1.67 vs. 7.5±1.64 days, respectively, p=0.009; difference 2.7 days [1.5–3.7]). The absence of dynamics of lung lesion volume on CT scans was rare: 1.2% [95% CI: 0.0–3.5] in the UMF group and 4.5% [0.12–8.89] in the IFN group, respectively (p>0.05). UMF reduced the risks of SARS-CoV-2 RNA re-isolation at the time of clinical recovery (days 6–9 of illness) by 19.0% [95% CI: 3.6–34.5]; OR 0.402 [0.199–0.810]; OR 0.310 [95% CI: 0.299–0.779] (12.8% versus 31.8%, respectively, p=0.010). There were no adverse events with the use of UMF and IFN.

Conclusion: The use of UMF for the treatment of non-severe COVID-19 in children has some clinical advantages compared to the intranasal form of IFN. UMF reduced the risks of lack of virological sanitation at the time of clinical recovery. It is advisable to conduct additional pediatric prospective studies to determine the therapeutic and antiviral potential in COVID-19 caused by new SARS-CoV2 variants.

全文:

受限制的访问

作者简介

Elena Meskina

Moscow Regional Research Clinical Institute named after M.F. Vladimirsky

编辑信件的主要联系方式.
Email: meskinaelena@rambler.ru
ORCID iD: 0000-0002-1960-6868

Dr. Sci. (Med.), Head of the Children’s Infectious Diseases Department, Professor at the Department of Children’s Diseases, Faculty of Continuous Medical Education

俄罗斯联邦, Moscow

Marima Khadisova

Moscow Regional Research Clinical Institute named after M.F. Vladimirsky

Email: murzabekova.marina.1979@mail.ru
ORCID iD: 0000-0001-8293-6643

Cand. Sci. (Med.), Senior Researcher, Children’s Infectious Diseases Department, Professor at the Department of Children’s Diseases, Faculty of Continuous Medical Education

俄罗斯联邦, Moscow

Elena Tselipanova

Moscow Regional Research Clinical Institute named after M.F. Vladimirsky

Email: elena-tselip@yandex.ru
ORCID iD: 0000-0002-0586-8402

Cand. Sci. (Med.), Senior Researcher, Children’s Infectious Diseases Department, Professor at the Department of Children’s Diseases, Faculty of Continuous Medical Education

俄罗斯联邦, Moscow

Lidiya Galkina

Moscow Regional Research Clinical Institute named after M.F. Vladimirsky

Email: lidiya140855@mail.ru
ORCID iD: 0000-0002-0052-2867

Cand. Sci. (Med.), Senior Researcher, Children’s Infectious Diseases Department, Professor at the Department of Children’s Diseases, Faculty of Continuous Medical Education

俄罗斯联邦, Moscow

参考

  1. Li G., Hilgenfeld R., Whitley R., De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449–475. doi: 10.1038/s41573-023-00672-y.
  2. Kröker A., Tirzīte M. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. Respir Res. 2021;22(1):304. doi: 10.1186/s12931-021-01885-8.
  3. Brady D.K., Gurijala A.R., Huang L., et al. A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection. FEBS J. 2024;291(8):1632–1662. doi: 10.1111/febs.16662.
  4. Gudima G., Kofiadi I., Shilovskiy I., et al. Antiviral Therapy of COVID-19. Int J Mol Sci. 2023;24(10):8867. doi: 10.3390/ijms24108867.
  5. Cho J., Shin Y., Yang J.S., et al. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants. Antiviral Res. 2023;214:105609. doi: 10.1016/j.antiviral.2023.105609.
  6. Lv B., Gao X., Zeng G., et al. Safety Profile of Paxlovid in the Treatment of COVID-19. Curr Pharm Des. 2024;30(9):666–675. doi: 10.2174/0113816128280987240214103432.
  7. Saravolatz L.D., Depcinski S., Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clin Infect Dis. 2023;76(1):165–171. doi: 10.1093/cid/ciac180.
  8. Chavda V., Dodiya P., Apostolopoulos V. Adverse drug reactions associated with COVID-19 management. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(10):7353–7376. doi: 10.1007/s00210-024-03137-0.
  9. Pannu V., Udongwo N., Imburgio S., et al. Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database. Ann Pharmacother. 2024;58(2):105–109. doi: 10.1177/10600280231169256.
  10. Meyerowitz E.A., Li Y. Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses. Clin Infect Dis. 2024;78(4):908–917. doi: 10.1093/cid/ciad685.
  11. Arabi M., Al-Najjar Y., Mhaimeed N., et al. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review. J Cell Mol Med. 2023;27(11):1443–1464. doi: 10.1111/jcmm.17747.
  12. Puhach O., Meyer B., Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21(3):147–161. doi: 10.1038/s41579-022-00822-w.
  13. Ленева И.А., Пшеничная Н.Ю., Булгакова В.А. Умифеновир и коронавирусные инфекции: обзор результатов исследований и опыта применения в клинической практике. Терапевтический архив. 2020;92(11):91–97. [Leneva I.A., Pshenichnaya N.Y., Bulgakova V.A. Umifenovir and coronavirus infections: a review of research results and clinical practice. Therapeutic Archive. 2020;92(11):91–97. (In Russ.)]. doi: 10.26442/00403660.2020.11.00071.
  14. Shuster A., Pechalrieu D., Jackson C.B., et al. Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein. ACS Chem. Biol. 2021;16:2845–2851. doi: 10.1021/acschembio.1c00756.
  15. Leneva I., Kartashova N., Poromov A., et al. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses. 2021;13(8):1665. doi: 10.3390/v13081665.
  16. Walter M.R. The Role of Structure in the Biology of Interferon Signaling. Front. Immunol. 2020;11:606489. doi: 10.3389/fimmu.2020.606489.
  17. Пшеничная Н.Ю., Булгакова В.А., Львов Н.И. и др. Клиническая эффективность умифеновира при гриппе и ОРВИ (исследование АРБИТР). Терапевтический архив. 2019;91(3):56–63. [Pshenichnaya N.Y., Bulgakova V.A., Lvov N.I., et al. Clinical efficacy of umifenovir in influenza and acute respiratory viral infections (ARBITR study). Therapeutic Archive. 2019; 91(3):56–63. doi: 10.26442/00403660.2019.03.000127. (In Russ.)].
  18. Шамшева О.В., Молочкова О.В. Спектр применения отечественного противовирусного препарата в педиатрии. Детские инфекции. 2015;4:26–30. [Shamsheva O.V., Molochkova O.V. The Range of Application of Domestic Antiviral Drug in Рediatrics. Children infections. 2015;14(4):26–30. doi: 10.22627/2072-8107-2015-14-4-26-30. (In Russ.)].
  19. Yu M., Wang D.C., Li S., et al. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019. J Med Virol. 202;94(4):1513–1522. doi: 10.1002/jmv.27481.
  20. Акимкин В.Г., Баранов И.И., Беженарь В.Ф. и др. Интерфероны: роль в патогенезе, место в терапии и профилактике заболеваний вирусной и бактериальной этиологии. М., 2024. 304 c. [Akimkin V.G., Baranov I.I., Refugee V.F., et al. Interferons: role in pathogenesis, place in therapy and prevention of diseases of viral and bacterial etiology. M., 2024. 304 p. (In Russ.)].
  21. Reis S., Metzendorf M.I., Kuehn R., et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev. 2023;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
  22. Huang D., Yu H., Wang T., et al. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2020;93:481–490. doi: 10.1002/jmv.26256.
  23. Amani B., Amani B., Zareei S., Zareei M. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis. Immun Inflamm Dis. 2021;9:1197–1208. doi: 10.1002/iid3.502.
  24. He X.L., Zhou Y.Y., Fu W., et al. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study. Curr Med Sci. 2021;41(6):1096–1104. doi: 10.1007/s11596-021-2434-y.
  25. Nojomi M., Yassin Z., Keyvani H., et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20(1):954. doi: 10.1186/s12879-020-05698-w.
  26. Wei S., Xu S., Pan Y.H. Efficacy of arbidol in COVID-19 patients: A retrospective study. World J Clin Cases. 2021;9(25):7350–7357. doi: 10.12998/wjcc.v9.i25.7350/
  27. Ramachandran R., Bhosale V., Reddy H., et al. Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. Int J Infect Dis. 2022;115:62–69. doi: 10.1016/j.ijid.2021.11.025.
  28. Lohse Z.M, Shapiro J.J., Lednicky J.A., et al. Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Children and Utility of Rapid Antigen Testing as an Indicator of Culturable Virus. Clin Infect Dis. 2023;76(3):e491–e494. doi: 10.1093/cid/ciac693.
  29. Zuo W., He D., Liang C., et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. 2024;24(8):845–855. doi: 10.1016/S1473-3099(24)00171-3.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025